Integrative meta-analysis for the identification of hub genes in chemoresistant colorectal cancer.
Conclusion: Our findings show that HNF4A could be a potential target in overcoming FOLFOX chemoresistance in colorectal cancer. PMID: 32462912 [PubMed - as supplied by publisher]
CONCLUSION: The therapeutic benefit of additional substances is less distinct in patients with RAS mutated as compared to RAS wildtype metastatic colorectal cancer, especially with regard to OS. PMID: 32561975 [PubMed - indexed for MEDLINE]
A 40 years old male with colorectal cancer, with an unbalanced hypercaloric diet, attempted, on his own initiative, to gain weight, without nutritional follow-up, during chemotherapy treatment with oxaliplatin protocols, without pharmaceutical guidance. When initiating the new protocol, with oxaliplatin/irinotecan combination therapy, he presented symptomatology suggestive of hepatic injury during the administration of oxaliplatin. When performing a Magnetic Resonance Imaging of the total abdomen, hepatic nodules were identified indicating lesions resulting from the chemotherapy treatment, and blood tests indicated Asparta...
Conclusion: To improve the treatment efficacy of oxaliplatin-based therapy in advanced CRC patients, adding antibiotics is a potential therapeutic option. PMID: 32655636 [PubMed]
CONCLUSIONS: In the CRCSA cohort from Johannesburg, comorbidity is uncommon, with no significant adverse effect on OS. If potentially curative treatment is initiated within 40 days of CRC diagnosis, OS could be improved. To fully understand the epidemiology of CRC in SA, population-based registries are essential, and future research should aim to identify health system failures that lead to delays in intervention beyond 40 days in patients with CRC. PMID: 32657722 [PubMed - as supplied by publisher]
Publication date: Available online 13 July 2020Source: Pathology - Research and PracticeAuthor(s): Hyun Ji Son, Ha Yoon Mo, Nam Jin Yoo, Sug Hyung Lee
Basel, 14 July 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Blueprint Medicines Corporation (NASDAQ:BPMC), today announced the signing of a licensing and collaboration agreement providing exclusive rights to Roche for global co-development and commercialisation outside the United States (US), excluding Greater China*. In the US, Genentech, a member of the Roche Group, will obtain co-commercialisation rights to pralsetinib, Blueprint Medicine ’s investigational, once-daily oral precision therapy for the treatment of people with RET-altered ...
Journal of Medicinal ChemistryDOI: 10.1021/acs.jmedchem.0c00929
The introduction of complete mesocolic excision (CME) with central vascular ligation (CVL) for right-sided colon cancer has improved the oncologic outcomes. Recently, we have introduced a modified CME (mCME) p...